AMENDMENTS TO THE SPECIFICATION

On page 1 of the specification, please amend the first paragraph with the following revised paragraph:

The present Application is a 35 U.S.C. § 371 U.S. national-phase application of International Application No. PCT/US2004/015786, international filing date of 20 May 2004, which claims priority to U.S. Application Serial Number 10/849,615, filed May 20, 2004, now abandoned, and U.S. Provisional Application Serial Number 60/471,958 filed May 20, 2003.

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application

1-33. (canceled)

34. (previously presented) A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain variable region and a heavy chain variable region, wherein:

the light chain variable region comprises:

a CDRL1 amino acid sequence of SEQ ID NO:5;

a CDRL2 amino acid sequence of SEQ ID NO:13;

a CDRL3 amino acid sequence SEQ ID NO:19, and

the heavy chain variable region comprises:

a CDRH1 amino acid sequence of SEQ ID NO:25;

a CDRH2 amino acid sequence of SEQ ID NO:39; and

a CDRH3 amino acid sequence of SEQ ID NO:57

35-39. (canceled)

40. (withdrawn) A method of treating B cell lymphoma comprising administering to a subject a composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain variable region and a heavy chain variable region, wherein:

the light chain variable region comprises:

a CDRL1 amino acid sequence of SEQ ID NO:5;

a CDRL2 amino acid sequence of SEQ ID NO:13; and

a CDRL3 amino acid sequence of SEQ ID NO:19, and

the heavy chain variable region comprises:

a CDRH1 amino acid sequence of SEQ ID NO:25;

a CDRH2 amino acid sequence of SEQ ID NO:39; and

a CDRH3 amino acid sequence of SEQ ID NO:57.

41. (withdrawn) The method of Claim 40, wherein the CD20 binding molecule comprises the AME 33 Fab.

42. (withdrawn) The method of Claim 40, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 5.0×10^{-10} M or less, and a dissociation rate (koff) for human CD20 of 5.0×10^{-4} s^{-1} or less.

43. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 1.5×10^{-10} M or less.

44. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has a dissociation rate (k_{off}) for human CD20 of 2.5×10^{-4} s^{-1} or less.

45. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has an association rate (k_{on}) for human CD20 of 5.0×10^{-5} M^{-1} s^{-1} or greater.

46. (withdrawn) The method of Claim 40, wherein the B cell lymphoma is Non-Hodgkin's lymphoma.

47. (withdrawn) The method of Claim 46, wherein the Non-Hodgkin's lymphoma is Waldenstrom's macroglobulinemia.

48. (previously presented) The composition of Claim 34, wherein the light chain variable region comprises an amino acid sequence of SEQ ID NO:59 and the heavy chain variable region comprises an amino acid sequence of SEQ ID NO:61.

49-50. (canceled)

51. (previously presented) A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain amino acid sequence of SEQ ID NO:67 and a heavy chain amino acid sequence of SEQ ID NO:69.